Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling.
Soyoung KangSeungwon YangJongsung HahnJune Young JangKyoung Lok MinJin WiMin Jung ChangPublished in: Journal of clinical medicine (2022)
We established a population pharmacokinetic model for meropenem in patients receiving V-A ECMO and revealed that it is not necessary to adjust the dosage depending on V-A ECMO. Instead, more aggressive treatment is needed than that of standard treatment, and higher dosage is required without continuous renal replacement therapy (CRRT). Also, extended infusion could lead to better target attainment, and we could provide updated nomograms of the meropenem dosage regimen.
Keyphrases
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- end stage renal disease
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- respiratory failure
- heart failure
- low dose
- acute kidney injury
- patient reported outcomes
- intensive care unit
- mechanical ventilation
- multidrug resistant
- combination therapy
- replacement therapy